VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial
John Wilson, Xiaojun You, Matt J. Ellis, Don S. Urquhart, Lokesh K. Jha, Margaret Duncan, Simon Tian, Ryan A. Harris, Tom Kotsimbos, D. Keating
Topics & Concepts
IvacaftorCystic fibrosisMedicinePhysical therapyInternal medicineCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesChronic Obstructive Pulmonary Disease (COPD) ResearchDelphi Technique in Research